(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Disc Medicine's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IRON's revenue for 2026 to be $461,535,224, with the lowest IRON revenue forecast at $461,535,224, and the highest IRON revenue forecast at $461,535,224. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $762,199,507, with the lowest IRON revenue forecast at $88,629,572, and the highest IRON revenue forecast at $1,350,052,232.
In 2028, IRON is forecast to generate $3,906,710,560 in revenue, with the lowest revenue forecast at $3,118,768,741 and the highest revenue forecast at $5,259,280,257.